• • Haploidentical stem cell transplantation in DOCK8 deficiency – successful control of pre-existing severe viremia with a TCRaß/CD19-depleted graft and antiviral treatment.
    Ghosh S, Schuster FR, Adams O, Babor F, Borkhardt A, Comoli P, Handgretinger R, Lang P, Laws HJ, Siepermann M, Meisel R.
    Clin Immunol. 2014 Mar 22. pii: S1521-6616(14)00070-9.
  • Mycoplasma salivarium as a Dominant Coloniser of Fanconi Anaemia Associated Oral Carcinoma.
    Henrich B, Rumming M, Sczyrba A, Velleuer E, Dietrich R, Gerlach W, Gombert M, Rahn S, Stoye J, Borkhardt A, Fischer U.
    PLoS One. 2014 Mar 18;9(3):e92297.
  • RAG1 deficiency with a shifting B cell phenotype and chromosomal instability.
    Ghosh S, Hönscheid A, Schwarz K, Eirich K, Schindler D, Schönberger S, Speckmann C, Borkhardt A, Laws HJ.
    Clin Immunol. 2014 Feb 26. pii: S1521-6616(14)00046-1.
  • CLASS SWITCH RECOMBINATION PROCESS IN ATAXIA TELANGIECTASIA PATIENTS WITH ELEVATED SERUM LEVELS OF IgM.
    Mohammadinejad P, Abolhassani H, Aghamohammadi A, Pourhamdi S, Ghosh S, Sadeghi B, Nasiri Kalmarzi R, Durandy A, Borkhardt A.
    J Immunoassay Immunochem. 2014 Feb 25.
  • Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy.
    Vicente-Dueñas C, Hauer J, Ruiz-Roca L, Ingenhag D, Rodríguez-Meira A, Auer F, Borkhardt A, Sánchez-García I.
    Semin Cancer Biol. 2014 Feb 12. pii: S1044-579X(14)00025-X.
  • Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.
    Garcia-Cuellar MP, Füller E, Mäthner E, Breitinger C, Hetzner K, Zeitlmann L, Borkhardt A, Slany RK.
    Leukemia. 2014 Jan 21.
  • CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B, Milosevic S, Doessinger G, Reuther S, Liepert A, Braeu M, Schick J, Vogt V, Schuster F, Kroell T, Busch DH, Borkhardt A, Kolb HJ, Tischer J, Buhmann R, Schmetzer H.
    Immunobiology. 2014 Apr;219(4):247-60.
  • Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A.
    Auer F, Rüschendorf F, Gombert M, Husemann P, Ginzel S, Izraeli S, Harit M, Weintraub M, Weinstein OY, Lerer I, Stepensky P, Borkhardt A, Hauer J.
    Leukemia. 2013 Nov 29.
  • The impact of TEL-AML1 (ETV6-RUNX1) expression in precursor B cells and implications for leukaemia using three different genome-wide screening methods.
    Linka Y, Ginzel S, Krüger M, Novosel A, Gombert M, Kremmer E, Harbott J, Thiele R, Borkhardt A, Landgraf P.
    Blood Cancer J. 2013 Oct 11;3:e151.
  • HIV-1 seroreversion in HIV-1-infected children: do genetic determinants play a role?
    Asang C, Laws HJ, Adams O, Enczmann J, Feiterna-Sperling C, Notheis G, Buchholz B, Borkhardt A, Neubert J.
    AIDS. 2014 Feb 20;28(4):543-7.
  • Whole-genome paired-end analysis confirms remarkable genomic stability of atypical teratoid/rhabdoid tumors.
    Hoell JI, Gombert M, Bartenhagen C, Ginzel S, Husemann P, Felsberg J, Reifenberger G, Eggert A, Dugas M, Schönberger S, Borkhardt A, Fischer U.
    Genes Chromosomes Cancer. 2013 Oct;52(10):983-5.
  • COL2A1 mutation as a cause of premature osteoarthritis in a 13-year-old child.
    Lankisch P, Hönscheid A, Schaper J, Borkhardt A, Laws HJ.
    Joint Bone Spine. 2014 Jan;81(1):83-5.
  • Anti-leukaemic activity of a novel haploidentical-transplantation approach employing unmanipulated bone marrow followed by CD6-depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia.
    Schuster FR, Meisel R, Führer M, Reuther S, Hauer J, Tischer J, Feuchtinger T, Laws HJ, Kolb HJ, Borkhardt A.
    Br J Haematol. 2013 Sep;162(6):802-7.
  • Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Schrauder A, Escherich G, Sramkova L, Niggli F, Hitzler J, von Stackelberg A.
    J Clin Oncol. 2013 Jul 20;31(21):2736-42.
  • Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
    Parvaneh N, Filipovich AH, Borkhardt A.
    Br J Haematol. 2013 Sep;162(5):573-86.
  • Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a β chain CDR3 sequence associated with hepatitis-induced pathogenesis.
    Krell PF, Reuther S, Fischer U, Keller T, Weber S, Gombert M, Schuster FR, Asang C, Stepensky P, Strahm B, Meisel R, Stoye J, Borkhardt A.
    Haematologica. 2013 Sep;98(9):1388-96.
  • Cytogenetic aspects of childhood leukemias.
    Lampert F, Harbott J, Borkhardt A.
    Klin Padiatr. 2013 May;225 Suppl 1:S30-3.
  • Agammaglobulinemia and lack of immunization protection in exudative atopic dermatitis.
    Lankisch P, Laws HJ, Weiss M, Borkhardt A.
    Eur J Pediatr. 2014 Jan;173(1):117-9.
  • The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy.
    Stepensky P, Saada A, Cowan M, Tabib A, Fischer U, Berkun Y, Saleh H, Simanovsky N, Kogot-Levin A, Weintraub M, Ganaiem H, Shaag A, Zenvirt S, Borkhardt A, Elpeleg O, Bryant NJ, Mevorach D.
    Blood. 2013 Jun 20;121(25):5078-87.
  • Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia.
    Chen C, Bartenhagen C, Gombert M, Okpanyi V, Binder V, Röttgers S, Bradtke J, Teigler-Schlegel A, Harbott J, Ginzel S, Thiele R, Fischer U, Dugas M, Hu J, Borkhardt A.
    Genes Chromosomes Cancer. 2013 Jun;52(6):564-79.
  • Testing for herpesvirus infection is essential in children with chromosomal-instability syndromes.
    Lankisch P, Adler H, Borkhardt A.
    J Virol. 2013 Mar;87(6):3616-7.
  • MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways.
    Daschkey S, Röttgers S, Giri A, Bradtke J, Teigler-Schlegel A, Meister G, Borkhardt A, Landgraf P.
    PLoS One. 2013;8(2):e56334.
  • Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
    Neubert J, Pfeffer M, Borkhardt A, Niehues T, Adams O, Bolten M, Reuter S, Stannigel H, Laws HJ.
    BMC Pregnancy Childbirth. 2013 Jan 24;13:22.
  • Recurrent involvement of ring-type zinc finger genes in complex molecular rearrangements in childhood acute myelogeneous leukemia with translocation t(10;11)(p12;q23).
    Ghosh S, Bartenhagen C, Okpanyi V, Gombert M, Binder V, Teigler-Schlegel A, Bradtke J, Röttgers S, Dugas M, Borkhardt A.
    Leukemia. 2013 Aug;27(8):1745-8.
  • Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer. 2013 Apr;49(6):1346-55.
  • Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.
    Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; ICGC MMML-Seq Project.
    Nat Genet. 2012 Dec;44(12):1316-20.
  • Treosulfan-based conditioning in DOCK8 deficiency: complete lympho-hematopoietic reconstitution with minimal toxicity.
    Ghosh S, Schuster FR, Fuchs I, Laws HJ, Borkhardt A, Meisel R.
    Clin Immunol. 2012 Dec;145(3):259-61.
  • Allo-SCT using BU, CY and melphalan for children with AML in second CR.
    Beier R, Albert MH, Bader P, Borkhardt A, Creutzig U, Eyrich M, Ehlert K, Gruhn B, Greil J, Handgretinger R, Holter W, Klingebiel T, Kremens B, Lang P, Mauz-Körholz C, Meisel R, Müller I, Peters C, Reinhardt D, Sedlacek P, Schulz A, Schuster FR, Schrauder A, Strahm B, Sykora KW, Wössmann W, Zimmermann M, Sauer MG.
    Bone Marrow Transplant. 2013 May;48(5):651-6.
  • Homeobox protein HB9 binds to the prostaglandin E receptor 2 promoter and inhibits intracellular cAMP mobilization in leukemic cells.
    Wildenhain S, Ingenhag D, Ruckert C, Degistirici Ö, Dugas M, Meisel R, Hauer J, Borkhardt A.
    J Biol Chem. 2012 Nov 23;287(48):40703-12.
  • Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin’s lymphoma (HL).
    Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, Borkhardt A, Seeger K, Lehrnbecher T, Kulozik A, Rößler J, Burdach S, Jürgens H, Körholz D.
    Klin Padiatr. 2012 Oct;224(6):377-81.
  • Lack of association between KIR genes and acute lymphoblastic leukemia in children.
    Babor F, Manser A, Schönberg K, Enczmann J, Borkhardt A, Meisel R, Uhrberg M.
    Blood. 2012 Sep 27;120(13):2770-2.
  • Epidemiology and clinical characteristics of pandemic (H1N1) 2009 influenza infection in pediatric hemato-oncology and hematopoietic stem cell transplantation patients.
    Babor F, Grund S, Siepermann M, Oommen PT, Kuhlen M, Schuster FR, Laws HJ, Wessalowski R, Bienemann K, Janßen G, Adams O, Borkhardt A, Meisel R.
    Transpl Infect Dis. 2012 Dec;14(6):589-94.
  • Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function.
    Ghosh S, Adams O, Schuster FR, Borkhardt A, Meisel R.
    Transpl Infect Dis. 2012 Dec;14(6):657-9.
  • EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors.
    Schönberger S, Okpanyi V, Calaminus G, Heikaus S, Leuschner I, Nicholson JC, Stoecklein NH, Schneider DT, Borkhardt A.
    Genes Chromosomes Cancer. 2013 Jan;52(1):24-32.
  • Human leukocyte antigen distribution in German Caucasians with advanced Ewing’s sarcoma.
    Thiel U, Wolf P, Wawer A, Blaeschke F, Grunewald TG, von Lüttichau IT, Klingebiel T, Bader P, Borkhardt A, Laws HJ, Handgretinger R, Lang P, Schlegel PG, Eyrich M, Gruhn B, Ehninger G, Koscielniak E, Klein C, Sykora KW, Holler E, Mauz-Körholz C, Woessmann W, Richter GH, Schmidt AH, Peters C, Dirksen U, Jürgens H, Bregni M, Burdach S.
    Klin Padiatr. 2012 Oct;224(6):353-8.
  • Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
    Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S, Schwendinger M, Haas OA, Fritsch G, Pickl WF, Förster-Waldl E, Borkhardt A, Boztug K, Bienemann K, Seidel MG.
    Haematologica. 2013 Mar;98(3):473-8.
  • A novel mtDNA large-scale mutation clinically exclusively presenting with refractory anemia: is there a chance to predict disease progression?
    Binder V, Steenpass L, Laws HJ, Ruebo J, Borkhardt A.
    J Pediatr Hematol Oncol. 2012 May;34(4):283-92.
  • Invasive aspergillosis in pediatric oncology patients: a rare event with poor prognosis–case analysis to plan better targeted prophylactic or therapeutic measurement.
    Babor F, Schuster F, Mackenzie C, Meisel R, Schaper J, Sabir H, Siepermann M, Wessalowski R, Janßen G, Borkhardt A, Laws HJ.
    Klin Padiatr. 2012 Apr;224(3):160-5.
  • Raising hematology’s European voice: the importance of calling yourself a hematologist.
    de Wit TD, Borkhardt A, Chomienne C, Döhner H, Fibbe WE, Foà R, Hagenbeek A, Skoda RC, Smand CR, Jäger U.
    Haematologica. 2012 Apr;97(4):476-8.
  • IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
    Mansouri D, Mahdaviani SA, Khalilzadeh S, Mohajerani SA, Hasanzad M, Sadr S, Nadji SA, Karimi S, Droodinia A, Rezaei N, Linka RM, Bienemann K, Borkhardt A, Masjedi MR, Velayati AA.
    Int Arch Allergy Immunol. 2012;158(4):418-22.
  • MiR-125 in normal and malignant hematopoiesis.
    Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S.
    Leukemia. 2012 Sep;26(9):2011-8.
  • In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping.
    Reuther S, Schmetzer H, Schuster FR, Krell P, Grabrucker C, Liepert A, Kroell T, Kolb HJ, Borkhardt A, Buhmann R.
    Clin Exp Med. 2013 Feb;13(1):29-48.
  • Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.
    Ghosh S, Schuster FR, Binder V, Niehues T, Baldus SE, Seiffert P, Laws HJ, Borkhardt A, Meisel R.
    J Clin Immunol. 2012 Jun;32(3):438-40.
  • CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL.
    Fischer U, Ruckert C, Hubner B, Eckermann O, Binder V, Bakchoul T, Schuster FR, Merk S, Klein HU, Führer M, Dugas M, Borkhardt A.
    Haematologica. 2012 Sep;97(9):1304-11.
  • Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases.
    Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, Krux F, Synaeve C, Deenen R, Ginzel S, Dvorsky R, Gombert M, Halenius A, Hartig R, Helminen M, Fischer A, Stepensky P, Vettenranta K, Köhrer K, Ahmadian MR, Laws HJ, Fleckenstein B, Jumaa H, Latour S, Schraven B, Borkhardt A.
    Leukemia. 2012 May;26(5):963-71.
  • A Novel mtDNA Large-Scale Mutation Clinically Exclusively Presenting with Refractory Anemia: Is There a Chance To Predict Disease Progression?
    Binder V, Steenpass L, Laws HJ, Ruebo J, Borkhardt A.
    J Pediatr Hematol Oncol. 2012 Jan 12.
  • Association of nephrotic syndrome with immune reconstitution inflammatory syndrome.
    Lankisch P, Laws HJ, Wingen AM, Borkhardt A, Niehues T, Neubert J.
    Pediatr Nephrol. 2012 Apr;27(4):667-9.
  • RNA targets of wild-type and mutant FET family proteins.
    Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, Farazi TA, Hafner M, Borkhardt A, Sander C, Tuschl T.
    Nat Struct Mol Biol. 2011 Nov 13;18(12):1428-31.
  • Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.
    Siepermann M, Koscielniak E, Dantonello T, Klee D, Boos J, Krefeld B, Borkhardt A, Hoehn T, Asea A, Wessalowski R.
    Pediatr Blood Cancer. 2012 Jan;58(1):104-6.
  • CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12.
    Mulaw MA, Krause A, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK.
    Leukemia. 2012 May;26(5):1012-9.
  • Palliative sedation in 2 children with terminal cancer – an effective treatment of last resort in a home care setting.
    Kuhlen M, Schneider K, Richter U, Borkhardt A, Janssen G.
    Klin Padiatr. 2011 Nov;223(6):374-5.
  • Array-based sequence capture and next-generation sequencing for the identification of primary immunodeficiencies.
    Ghosh S, Krux F, Binder V, Gombert M, Niehues T, Feyen O, Laws HJ, Borkhardt A; PID-NET: German Network on Primary Immunodeficiency Diseases.
    Scand J Immunol. 2012 Mar;75(3):350-4.
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.
    Rettinger E, Willasch AM, Kreyenberg H, Borkhardt A, Holter W, Kremens B, Strahm B, Woessmann W, Mauz-Koerholz C, Gruhn B, Burdach S, Albert MH, Schlegel PG, Klingebiel T, Bader P.
    Blood. 2011 Nov 17;118(20):5681-8.
  • Severe encephalopathy, lactic acidosis, vegetative instability and neuropathy with 5-Fluorouracil treatment – pyrimidine degradation defect or beriberi?
    Rosen A, van Kuilenburg A, Assmann B, Kuhlen M, Borkhardt A.
    Case Rep Oncol. 2011 May;4(2):371-6.
  • Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
    Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A.
    Br J Haematol. 2011 Nov;155(4):468-76.
  • Induction maintenance concept for HAART as initial treatment in HIV infected infants.
    Ghosh S, Neubert J, Niehues T, Adams O, Morali-Karzei N, Borkhardt A, Laws HJ.
    Eur J Med Res. 2011 Jun 21;16(6):243-8.
  • iNKT cell frequency in peripheral blood of Caucasian children and adolescent: the absolute iNKT cell count is stable from birth to adulthood.
    Bienemann K, Iouannidou K, Schoenberg K, Krux F, Reuther S, Feyen O, Bienemann K, Schuster F, Uhrberg M, Laws HJ, Borkhardt A.
    Scand J Immunol. 2011 Oct;74(4):406-11.
  • Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia.
    Hauer J, Mullighan C, Morillon E, Wang G, Bruneau J, Brousse N, Lelorc’h M, Romana S, Boudil A, Tiedau D, Kracker S, Bushmann FD, Borkhardt A, Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M.
    Blood. 2011 Jul 21;118(3):544-53.
  • Rb and nucleolin antagonize in controlling human CD34 gene expression.
    Grinstein E, Mahotka C, Borkhardt A.
    Cell Signal. 2011 Aug;23(8):1358-65.
  • Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia.
    Schuster FR, Hubner B, Führer M, Eckermann O, Gombert M, Dornmair K, Binder V, Reuther S, Krell P, Keller T, Borkhardt A.
    Blood Cancer J. 2011 Mar;1(3):e8.
  • Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.
    Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B.
    Pediatr Blood Cancer. 2011 Apr;56(4):578-83.
  • No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients.
    Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S; Solid Tumor Working Party (STWP) and the Pediatric DiseaseWorking Party (PDWP) of the European Group for Blood and Marrow Transplantation (EBMT); Asia Pacific Blood and Marrow Transplantation (APBMT); Pediatric Registry for Stem Cell Transplantations (PRST); MetaEICESS Study Group.
    Ann Oncol. 2011 Jul;22(7):1614-21.
  • Analysis of the adenomatous polyposis coli (APC) gene in childhood and adolescent germ cell tumors.
    Okpanyi V, Schneider DT, Zahn S, Sievers S, Calaminus G, Nicholson JC, Palmer RD, Leuschner I, Borkhardt A, Schönberger S.
    Pediatr Blood Cancer. 2011 Mar;56(3):384-91.
  • IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
    Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB.
    Haematologica. 2011 Mar;96(3):472-6.
  • ALA-induced porphyrin accumulation in medulloblastoma and its use for fluorescence-guided surgery.
    Eicker S, Sarikaya-Seiwert S, Borkhardt A, Gierga K, Turowski B, Heiroth HJ, Steiger HJ, Stummer W.
    Cent Eur Neurosurg. 2011 May;72(2):101-3.
  • Dizygotic twins discordant for HIV-1 despite vertical transmission prophylaxis: was human leukocyte antigen homozygosity of disadvantage to the infected twin?
    Neubert J, Enczmann J, Krux F, Hower M, Borkhardt A, Laws HJ.
    AIDS. 2010 Sep 10;24(14):2295-6.
  • Magnetization transfer imaging provides no evidence of demyelination in methotrexate-induced encephalopathy.
    Miese FR, Schuster FR, Pierstorff K, Karenfort M, Laws HJ, Borkhardt A, Saleh A.
    AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):E110-2.
  • Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.
    Wildenhain S, Ruckert C, Röttgers S, Harbott J, Ludwig WD, Schuster FR, Beldjord K, Binder V, Slany R, Hauer J, Borkhardt A.
    Leukemia. 2010 Sep;24(9):1657-60.
  • Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia.
    Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Münster group.
    J Clin Oncol. 2010 Jul 1;28(19):3115-21.
  • ALK fusion genes in children with atypical myeloproliferative leukemia.
    Röttgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamerdinger U, Slany R, Harbott J, Borkhardt A.
    Leukemia. 2010 Jun;24(6):1197-200.
  • Where do the leukaemia relapses come from?
    Borkhardt A.
    J Mol Med (Berl). 2010 Mar;88(3):219-22.
  • HIV-1 seroreversion following antiretroviral therapy in an HIV-infected child initially presenting with acquired immunodeficiency syndrome.
    Neubert J, Laws HJ, Adams O, Münk C, Krämer M, Niehues T, Korn K, Fleckenstein B, Petri E, Borkhardt A.
    AIDS. 2010 Jan 16;24(2):327-8.
  • Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.
    Blood. 2010 Feb 4;115(5):1006-17.
  • Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.
    Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A, Edry L, Hertzberg L, Shomron N, Williams O, Trka J, Borkhardt A, Izraeli S.
    Leukemia. 2010 Jan;24(1):89-96.
  • Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S, Plehm S, Unland R, Dirksen U, Borkhardt A, Staege MS, Müller-Tidow C, Richter GH.
    Cell Cycle. 2009 Jul 1;8(13):1991-6.
  • Development of a specialised paediatric palliative home care service
    Kuhlen M, Balzer S, Richter U, Fritsche-Kansy M, Friedland C, Borkhardt A, Janssen G.
    Klin Padiatr. 2009 May-Jun;221(3):186-92.
  • Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation.
    Huck K, Feyen O, Niehues T, Rüschendorf F, Hübner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A.
    J Clin Invest. 2009 May;119(5):1350-8.
  • Reassessment of treatment modalities for paediatric patients with chronic immune thrombocytopenia.
    Laws HJ, Janssen G, Borkhardt A.
    Hamostaseologie. 2009 May;29(2):171-6.
  • Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
    Schuster FR, Buhmann R, Reuther S, Hubner B, Grabrucker C, Liepert A, Reibke R, Lichtner P, Yang T, Kroell T, Kolb HJ, Borkhardt A, Schmetzer H.
    Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):275-86.
  • Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A; ALL-REZ BFM Study Group.
    J Clin Oncol. 2009 Jan 20;27(3):377-84.
  • Saving the red baby: successful allogeneic cord blood transplantation in Omenn syndrome.
    Schönberger S, Ott H, Gudowius S, Wüller S, Baron JM, Merk HF, Lassay L, Megahed M, Feyen O, Laws HJ, Dilloo D, Borkhardt A, Niehues T.
    Clin Immunol. 2009 Mar;130(3):259-63.
  • Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome.
    Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin JP, Tal NB, Green AR, Izraeli S.
    Lancet. 2008 Oct 25;372(9648):1484-92.
  • Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.
    Tramsen L, Koehl U, Tonn T, Latgé JP, Schuster FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, Klingebiel T, Lehrnbecher T.
    Bone Marrow Transplant. 2009 Jan;43(1):13-9.
  • Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnafi V, MacIntyre E, Dal Cortivo L, Radford I, Brousse N, Sigaux F, Moshous D, Hauer J, Borkhardt A, Belohradsky BH, Wintergerst U, Velez MC, Leiva L, Sorensen R, Wulffraat N, Blanche S, Bushman FD, Fischer A, Cavazzana-Calvo M.
    J Clin Invest. 2008 Sep;118(9):3132-42.
  • An immunodeficiency disease with RAG mutations and granulomas.
    Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, Schneider DT, Manfras B, Pannicke U, Willemze R, Knüchel R, Göbel U, Schulz A, Borkhardt A, Friedrich W, Schwarz K, Niehues T.
    N Engl J Med. 2008 May 8;358(19):2030-8.
  • Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement.
    Hauer J, Tosi S, Schuster FR, Harbott J, Kolb HJ, Borkhardt A.
    Pediatr Blood Cancer. 2008 Apr;50(4):921-3.
  • Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia.
    Meissner B, Borkhardt A, Dilloo D, Fuchs D, Friedrich W, Handgretinger R, Peters C, Schrauder A, Schuster FR, Vormoor J, Maecker B, Sykora KW, Zintl F, Welte K, Sauer M.
    Bone Marrow Transplant. 2007 Nov;40(10):945-9.
  • Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.
    Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, Jeremias I.
    Oncogene. 2008 Jan 31;27(6):783-93.
  • Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.
    Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C, Kuttler C, Ellwart JW, Frankenberger B, Nössner E, Salat C, Bogner C, Borkhardt A, Kolb HJ, Krackhardt AM.
    Blood. 2007 Oct 15;110(8):2931-9.
  • A mammalian microRNA expression atlas based on small RNA library sequencing.
    Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foà R, Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T.
    Cell. 2007 Jun 29;129(7):1401-14.
  • Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma.
    Busch K, Keller T, Fuchs U, Yeh RF, Harbott J, Klose I, Wiemels J, Novosel A, Reiter A, Borkhardt A.
    Leukemia. 2007 Aug;21(8):1739-51.
  • Oral graft vs. host disease in children–treatment with topical tacrolimus ointment.
    Albert MH, Becker B, Schuster FR, Klein B, Binder V, Adam K, Nienhoff C, Führer M, Borkhardt A.
    Pediatr Transplant. 2007 May;11(3):306-11.
  • The application of siRNA technology to cancer biology discovery.
    Fuchs U, Borkhardt A.
    Adv Cancer Res. 2007;96:75-102.
  • Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
    Wossning T, Herzog S, Köhler F, Meixlsperger S, Kulathu Y, Mittler G, Abe A, Fuchs U, Borkhardt A, Jumaa H.
    J Exp Med. 2006 Dec 25;203(13):2829-40.
  • Development of a disease-specific quality of life questionnaire for children & adolescents with idiopathic thrombocytopenic purpura (ITP-QoL).
    von Mackensen S, Nilsson C, Jankovic M, Mirra N, D’Angelo E, Borkhardt A, Ljung R.
    Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):688-91.
  • Temporary blast reduction after immunoglobulin administration for congenital cytomegalovirus infection masking infant leukemia with cryptic MLL rearrangement.
    Metzler M, Bruch J, Stachel D, Langer T, Borkhardt A, Harbott J, Rascher W, Holter W.
    Leuk Res. 2007 Apr;31(4):553-7.
  • Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
    Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, Schneider B, Meyer C, Marschalek R, Borkhardt A, Pickl WF, Lion T, Gadner H, Haas OA, Dworzak MN.
    Clin Cancer Res. 2006 May 15;12(10):2988-94.
  • c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.
    Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, Frampton J, Slany RK.
    Blood. 2006 Jul 1;108(1):297-304.
  • MicroRNA in chronic lymphocytic leukemia.
    Borkhardt A, Fuchs U, Tuschl T.
    N Engl J Med. 2006 Feb 2;354(5):524-5.
  • Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome.
    Bojesen SE, Ammerpohl O, Weinhäusl A, Haas OA, Mettal H, Bohle RM, Borkhardt A, Fuchs U.
    Br J Cancer. 2006 Jan 30;94(2):323-32.
  • Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone.
    Verschoyle RD, Greaves P, Cai H, Borkhardt A, Broggini M, D’Incalci M, Riccio E, Doppalapudi R, Kapetanovic IM, Steward WP, Gescher AJ.
    Cancer Chemother Pharmacol. 2006 Jan;57(1):1-6.
  • Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.
    Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, Friedrich W, Ebell W, Borkhardt A, Bender-Goetze C.
    Blood. 2005 Sep 15;106(6):2102-4.
  • Treatment of relapsed acute myelogeneous leukaemia with MLL/AF 6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy.
    Schuster FR, Führer M, Woessmann W, Reiter A, Harbott J, Viehmann S, Borkhardt A.
    Leukemia. 2005 Jul;19(7):1273-4.
  • Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
    Wilda M, Perez AV, Bruch J, Woessmann W, Metzler M, Fuchs U, Borkhardt A.
    Genes Chromosomes Cancer. 2005 Aug;43(4):424-6.
  • NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms.
    Kracht T, Schrappe M, Strehl S, Reiter A, Elsner HA, Trka J, Cario G, Viehmann S, Harbott J, Borkhardt A, Metzler M, Langer T, Repp R, Marschalek R, Welte K, Haas OA, Stanulla M.
    Haematologica. 2004 Dec;89(12):1492-7.
  • RNA interference as a potential tool in the treatment of leukaemia.
    Borkhardt A, Heidenreich O.
    Expert Opin Biol Ther. 2004 Dec;4(12):1921-9.
  • Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia.
    Metzler M, Strissel PL, Strick R, Niemeyer C, Roettgers S, Borkhardt A, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Reinhardt D, Creutzig U, Beck JD, Rascher W, Repp R, Langer T.
    Genes Chromosomes Cancer. 2004 Nov;41(3):291-6.
  • Level of MYC overexpression in pediatric Burkitt’s lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.
    Wilda M, Busch K, Klose I, Keller T, Woessmann W, Kreuder J, Harbott J, Borkhardt A.
    Genes Chromosomes Cancer. 2004 Oct;41(2):178-82.
  • Silencing of disease-related genes by small interfering RNAs.
    Fuchs U, Damm-Welk C, Borkhardt A.
    Curr Mol Med. 2004 Aug;4(5):507-17.
  • Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt’s lymphoma for minimal residual disease analysis.
    Busch K, Borkhardt A, Wössmann W, Reiter A, Harbott J.
    Haematologica. 2004 Jul;89(7):818-25.
  • ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent.
    Woessmann W, Zwanzger D, Borkhardt A.
    Cell Biol Int. 2004;28(5):403-10.
  • RNA interference: new mechanisms for targeted treatment?
    Woessmann W, Damm-Welk C, Fuchs U, Borkhardt A.
    Rev Clin Exp Hematol. 2003 Sep;7(3):270-91.
  • Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL).
    Ritter U, Damm-Welk C, Fuchs U, Bohle RM, Borkhardt A, Woessmann W.
    Oligonucleotides. 2003;13(5):365-73.
  • Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy.
    Tuschl T, Borkhardt A.
    Mol Interv. 2002 Jun;2(3):158-67.
  • Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt’s lymphoma in children.
    Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A, Woessmann W.
    Leukemia. 2004 Mar;18(3):584-8.
  • Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
    Zeisig BB, Milne T, García-Cuéllar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK.
    Mol Cell Biol. 2004 Jan;24(2):617-28.
  • High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma.
    Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A.
    Genes Chromosomes Cancer. 2004 Feb;39(2):167-9.
  • Asymmetric multiplex-polymerase chain reaction – a high throughput method for detection and sequencing genomic fusion sites in t(4;11).
    Metzler M, Brehm U, Langer T, Viehmann S, Borkhardt A, Stanulla M, Schrappe M, Harbott J, Beck JD, Rascher W, Repp R.
    Br J Haematol. 2004 Jan;124(1):47-54.
  • Influence of stochastics on quantitative PCR in the detection of minimal residual disease.
    Rawer D, Borkhardt A, Wilda M, Kropf S, Kreuder J.
    Leukemia. 2003 Dec;17(12):2527-8; author reply 2528-31.
  • Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU.
    Neven B, Callebaut I, Prieur AM, Feldmann J, Bodemer C, Lepore L, Derfalvi B, Benjaponpitak S, Vesely R, Sauvain MJ, Oertle S, Allen R, Morgan G, Borkhardt A, Hill C, Gardner-Medwin J, Fischer A, de Saint Basile G.
    Blood. 2004 Apr 1;103(7):2809-15.
  • Early decompressive craniectomy and duraplasty for refractory intracranial hypertension in children: results of a pilot study.
    Ruf B, Heckmann M, Schroth I, Hügens-Penzel M, Reiss I, Borkhardt A, Gortner L, Jödicke A.
    Crit Care. 2003 Dec;7(6):R133-8.
  • The formin-binding protein 17, FBP17, binds via a TNKS binding motif to tankyrase, a protein involved in telomere maintenance.
    Fuchs U, Rehkamp GF, Slany R, Follo M, Borkhardt A.
    FEBS Lett. 2003 Nov 6;554(1-2):10-6.
    Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference.
    Damm-Welk C, Fuchs U, Wössmann W, Borkhardt A.
    Semin Cancer Biol. 2003 Aug;13(4):283-92.
  • Congenital leukaemia after heavy abuse of permethrin during pregnancy.
    Borkhardt A, Wilda M, Fuchs U, Gortner L, Reiss I.
    Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F436-7.
  • Occurrence of an MLL/LAF4 fusion gene caused by the insertion ins(11;2)(q23;q11.2q11.2) in an infant with acute lymphoblastic leukemia.
    Bruch J, Wilda M, Teigler-Schlegel A, Harbott J, Borkhardt A, Metzler M.
    Genes Chromosomes Cancer. 2003 May;37(1):106-9.
  • Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
    Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, Stanulla M, Schrappe M, Creutzig U, Ritter J, Leis T, Jacobs U, Harbott J, Beck JD, Rascher W, Repp R.
    Genes Chromosomes Cancer. 2003 Apr;36(4):393-401.
  • Higher disinfectant resistance of nosocomial isolates of Klebsiella oxytoca: indicator organisms in disinfectant testing are not reliable.
    Gortner L, Borkhardt A, Reiss I, Rüden H, Daschner F.
    J Hosp Infect. 2003 Feb;53(2):153-5.
  • New microRNAs from mouse and human.
    Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T.
    RNA. 2003 Feb;9(2):175-9.
  • The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21).
    Strehl S, Borkhardt A, Slany R, Fuchs UE, König M, Haas OA.
    Oncogene. 2003 Jan 9;22(1):157-60.
  • Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines.
    Woessmann W, Chen X, Borkhardt A.
    Cancer Chemother Pharmacol. 2002 Nov;50(5):397-404.
  • Polymorphisms of surfactant protein B encoding gene: modifiers of the course of neonatal respiratory distress syndrome?
    Makri V, Hospes B, Stoll-Becker S, Borkhardt A, Gortner L.
    Eur J Pediatr. 2002 Nov;161(11):604-8.
  • Blocking oncogenes in malignant cells by RNA interference–new hope for a highly specific cancer treatment?
    Borkhardt A.
    Cancer Cell. 2002 Sep;2(3):167-8.
  • Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases.
    Borkhardt A, Wuchter C, Viehmann S, Pils S, Teigler-Schlegel A, Stanulla M, Zimmermann M, Ludwig WD, Janka-Schaub G, Schrappe M, Harbott J.
    Leukemia. 2002 Sep;16(9):1685-90.
  • Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M, Fuchs U, Wössmann W, Borkhardt A.
    Oncogene. 2002 Aug 22;21(37):5716-24.
  • Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178).
    Ghadimi MP, Sanzenbacher R, Thiede B, Wenzel J, Jing Q, Plomann M, Borkhardt A, Kabelitz D, Janssen O.
    FEBS Lett. 2002 May 22;519(1-3):50-8.
  • Acute myeloid leukemia presenting with diabetes insipidus.
    Wössmann W, Borkhardt A, Gossen R, Göbel FJ, Reiter A.
    Eur J Pediatr. 2002 Mar;161(3):161-2.
  • Presence of N regions in the clonotypic DJ rearrangements of the immunoglobulin heavy-chain genes indicates an exquisitely short latency in t(4;11)-positive infant acute lymphoblastic leukemia.
    Fasching K, Panzer S, Haas OA, Borkhardt A, Marschalek R, Griesinger F, Panzer-Grümayer ER.
    Blood. 2001 Oct 1;98(7):2272-4.
  • An ins(X;11)(q24;q23) fuses the MLL and the Septin 6/KIAA0128 gene in an infant with AML-M2.
    Borkhardt A, Teigler-Schlegel A, Fuchs U, Keller C, König M, Harbott J, Haas OA.
    Genes Chromosomes Cancer. 2001 Sep;32(1):82-8.
  • The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia.
    Fuchs U, Rehkamp G, Haas OA, Slany R, Kōnig M, Bojesen S, Bohle RM, Damm-Welk C, Ludwig WD, Harbott J, Borkhardt A.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8756-61.
  • Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.
    Ferrari T, Weber B, Pils S, Harbott J, Borkhardt A.
    Ann Hematol. 2001 Feb;80(2):72-3.
  • Consequences of scientific reports of complications.
    Gortner L, Borkhardt A, Reiss I.
    Lancet. 2000 Dec 9;356(9246):2015.
  • Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants.
    Weber B, Borkhardt A, Stoll-Becker S, Reiss I, Gortner L.
    Turk J Pediatr. 2000 Jul-Sep;42(3):181-5.
  • Disinfectant contaminated with Klebsiella oxytoca as a source of sepsis in babies.
    Reiss I, Borkhardt A, Füssle R, Sziegoleit A, Gortner L.
    Lancet. 2000 Jul 22;356(9226):310.
  • Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
    Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, Ratei R, Ruppert V, Haferlach T, Creutzig U, Dörken B, Ludwig WD.
    Leukemia. 2000 Jul;14(7):1232-8.
  • The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q.
    Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D, Lampert F.
    Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9168-73.
  • A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells.
    Gillert E, Leis T, Repp R, Reichel M, Hösch A, Breitenlohner I, Angermüller S, Borkhardt A, Harbott J, Lampert F, Griesinger F, Greil J, Fey GH, Marschalek R.
    Oncogene. 1999 Aug 19;18(33):4663-71.
  • Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion.
    Loncarevic IF, Roitzheim B, Ritterbach J, Viehmann S, Borkhardt A, Lampert F, Harbott J.
    Genes Chromosomes Cancer. 1999 Mar;24(3):272-7.
  • Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
    Dördelmann M, Reiter A, Borkhardt A, Ludwig WD, Götz N, Viehmann S, Gadner H, Riehm H, Schrappe M.
    Blood. 1999 Aug 15;94(4):1209-17.
  • Multiplex PCR–a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia.
    Viehmann S, Borkhardt A, Lampert F, Harbott J.
    Ann Hematol. 1999 Apr;78(4):157-62.
  • Biology and clinical significance of the TEL/AML1 rearrangement.
    Borkhardt A, Harbott J, Lampert F.
    Curr Opin Pediatr. 1999 Feb;11(1):33-8.
  • A new fingerprint method for sequence analysis of chromosomal translocations at the genomic DNA level.
    Leis T, Repp R, Borkhardt A, Metzler M, Schläger F, Harbott J, Lampert F.
    Leukemia. 1998 May;12(5):758-63.
  • Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots.
    Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, Greaves MF.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4.
  • Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse.
    Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F.
    Blood. 1997 Dec 15;90(12):4933-7.
  • Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
    Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A.
    Blood. 1997 Jul 15;90(2):571-7.
  • Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
    Uphoff CC, MacLeod RA, Denkmann SA, Golub TR, Borkhardt A, Janssen JW, Drexler HG.
    Leukemia. 1997 Mar;11(3):441-7.
  • Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23).
    Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, Kreuder J, Hammermann J, Henn T, Lampert F.
    Oncogene. 1997 Jan 16;14(2):195-202.
  • Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J.
    Leukemia. 1996 Jun;10(6):957-63.
  • MLL/ENL fusion in congenital acute lymphoblastic leukemia with a unique t(11;18;19).
    Horstmann M, Argyriou-Tirita A, Borkhardt A, Kabisch H, Kapaun P, Winkler K, Haas OA.
  • Cancer Genet Cytogenet. 1996 Jun;88(2):103-9.

• • Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A.
    Kreuder J, Borkhardt A, Repp R, Pekrun A, Göttsche B, Gottschalk U, Reichmann H, Schachenmayr W, Schlegel K, Lampert F.
    N Engl J Med. 1996 Apr 25;334(17):1100-4.
  • Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas.
    Bohle RM, Brettreich S, Repp R, Borkhardt A, Kosmehl H, Altmannsberger HM.
    Am J Pathol. 1996 Mar;148(3):731-8.
  • Rapid detection of mitochondrial deletions by long-distance polymerase chain reaction.
    Kreuder J, Repp R, Borkhardt A, Lampert F.
    Eur J Pediatr. 1995 Dec;154(12):996.
  • Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.
    Drexler HG, Borkhardt A, Janssen JW.
    Leuk Lymphoma. 1995 Nov;19(5-6):359-80.
  • A novel type of MLL/AF10 fusion transcript in a child with acute megakaryocytic leukemia (AML-M7)
    Borkhardt A, Haas OA, Strobl W, Repp R, Mann G, Gadner H, Lampert F.
    Leukemia. 1995 Oct;9(10):1796-7.
  • Low frequency of RAS gene mutations and absence of mutations within the FLR exon of NF1 in patients with therapy-related leukemias.
    Borkhardt A, Brettreich S, Borkhardt AK, Repp R, Harbott J, Kreuder J, Lampert F.
    Leukemia. 1995 Oct;9(10):1790-1.
  • Is it possible to catch leukemia from a cat?
    Nowotny N, Uthman A, Haas OA, Borkhardt A, Lechner K, Egberink HF, Möstl K, Horzinek MC.
    Lancet. 1995 Jul 22;346(8969):252-3.
  • Construction of RNA standards for high-resolution automatic product analysis in quantitative competitive RT-PCR.
    Repp R, Borkhardt A, Gossen R, Kreuder J, Hammermann J, Lampert F.
    Biotechniques. 1995 Jul;19(1):84, 86-8, 90.
  • Rapid synthesis of hybrid RNA molecules associated with leukemia-specific chromosomal translocations.
    Borkhardt A, Mitteis M, Brettreich S, Schlieben S, Hammermann J, Repp R, Kreuder J, Buchen U, Lampert F.
    Leukemia. 1995 Apr;9(4):719-22.
  • Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines.
    Drexler HG, MacLeod RA, Borkhardt A, Janssen JW.
    Leukemia. 1995 Mar;9(3):480-500.
  • Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis.
    Repp R, Borkhardt A, Haupt E, Kreuder J, Brettreich S, Hammermann J, Nishida K, Harbott J, Lampert F.
    Leukemia. 1995 Jan;9(1):210-5.
  • Secondary acute myeloid leukemia with translocation (4;11) and MLL/AF4 rearrangement in a 15-year-old boy treated for common acute lymphoblastic leukemia 11 years earlier.
    Blütters-Sawatzki R, Borkhardt A, Grathwohl J, Repp R, Rheinisch-Becker I, Bohle RM, Lampert F.
    Ann Hematol. 1995 Jan;70(1):31-5.
  • Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission.
    Janssen JW, Ludwig WD, Borkhardt A, Spadinger U, Rieder H, Fonatsch C, Hossfeld DK, Harbott J, Schulz AS, Repp R, et al.
    Blood. 1994 Dec 1;84(11):3835-42.
  • Failure to detect BCR-ABL message in some Ph+ hematopoietic colonies: methodological aspects of the reverse transcriptase-polymerase chain reaction assay.
    Maekawa T, Repp R, Abe T, Borkhardt A, Lampert F.
    Blood. 1994 Nov 1;84(9):3240-1.
  • Spontaneous hematological remission in a boy with myelodysplastic syndrome and monosomy 7.
    Scheurlen W, Borkhardt A, Ritterbach J, Huppertz HI.
    Leukemia. 1994 Aug;8(8):1435-8.
  • Molecular analysis of MLL-1/AF4 recombination in infant acute lymphoblastic leukemia.
    Borkhardt A, Repp R, Haupt E, Brettreich S, Buchen U, Gossen R, Lampert F.
    Leukemia. 1994 Apr;8(4):549-53.
  • Detection of mycobacterial DNA from paraffin-embedded tissue in lung and lymphoid epithelial granulomas.
    Bohle RM, Heidemann A, Borkhardt A, Velcovsky HG, Altmannsberger HM.
    Verh Dtsch Ges Pathol. 1994;78:189-94.
  • BCR-ABL rearrangement in a child with acute myelogenous leukaemia without a Philadelphia chromosome.
    Borkhardt A, Repp R, Harbott J, Lakomek M, Janssen JW, Schlieben S, Bartram CR, Lampert F.
    Br J Haematol. 1993 Jun;84(2):341-2.
  • Quantification of leukaemic cells based on heteroduplex formation of tal-1 gene sequences after PCR coamplification.
    Borkhardt A, Repp R, Harbott J, Kreuder J, Lampert F.
    Br J Haematol. 1993 Jan;83(1):39-44.
  • Clinical and immunological aspects of hepatitis B virus infection in children receiving multidrug cancer chemotherapy.
    Repp R, von Hörsten B, Csecke A, Kreuder J, Borkhardt A, Willems WR, Lampert F, Gerlich WH.
    Arch Virol Suppl. 1993;8:103-11.
  • Frequency and DNA sequence of tal-1 rearrangement in children with T-cell acute lymphoblastic leukemia.
    Borkhardt A, Repp R, Harbott J, Keller C, Berner F, Ritterbach J, Lampert F.
    Ann Hematol. 1992 Jun;64(6):305-8.
  • Detection of a hepatitis B virus variant with a truncated X gene and enhancer II.
    Repp R, Keller C, Borkhardt A, Csecke A, Schaefer S, Gerlich WH, Lampert F.
    Arch Virol. 1992;125(1-4):299-304.

Justus Liebig Universität Gießen

• • 1990 – 1991 Assistenzarzt; Medizinische Akademie Magdeburg
    1990 Promotion an der Medizinische Akademie Magdeburg
    1984 – 1990 Medizinstudium an der Medizinischen Akademie Magdeburg

Funktionen in wissenschaftlichen Gesellschaften und Gremien (Auswahl)

• • seit 2009 Ratsmitglied des Vorstandes der Europäischen Gesellschaft für Hämatologie
    (European Hematology Association – EHA)

Auszeichnungen und verliehene Mitgliedschaften (Auswahl)

• • seit 2012 Mitglied der Nationalen Akademie der Wissenschaften Leopoldina
    2005 Carus-Medaille der Leopoldina und Carus-Preis der Stadt Schweinfurt
    2001 Preis der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie
    1998 Adalbert-Czerny-Preis der Deutschen Gesellschaft für Kinder- und Jugendmedizin

Main research interests:

• Leukemogenesis, bone marrow failure in children, bone marrow transplantation
  Role of fusion genes in leukemogenesis
  Diagnostics of chromosomal aberrations in leukemias
  Primary immunodeficiencies
  Function of microRNAs in the immune system and their role in malignant transformation of haematopoietic cells